Paper Details

  1. Home
  2. Paper Details

Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.

Author: LaneGeoff, MontesAna, SeshadriSrividya, WuntakalRekha

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Ovarian cancer is the seventh most common cancer in women, with about 1.3% of women developing it in their lifetime. Most ovarian cancers are of the epithelial type and often spread widely, requiring surgery and chemotherapy. Unfortunately, three out of four women with advanced epithelial ovarian cancer will experience a recurrence of the disease after treatment. While standard treatments like platinum-based drugs are effective, they can have side effects. LHRH agonists, a type of hormone therapy, have shown some promise in treating recurrent ovarian cancer, with fewer side effects than standard chemotherapy. More research is needed to better understand the role of LHRH agonists in treating this disease.
Paper Details　
Original Abstract of the Article :
Ovarian cancer is seventh most common cancer in women worldwide. Approximately 1.3% of women will be diagnosed with ovarian cancer at some point during their life time. The majority of tumours arise from surface of the ovary (epithelial). Two thirds of these women will present with advanced disease,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353126/

データ提供：米国国立医学図書館（NLM）

LHRH Agonists for Relapsed Epithelial Ovarian Cancer

This study examines the potential of luteinizing hormone releasing hormone (LHRH) agonists as a treatment for relapsed epithelial ovarian cancer (EOC). The researchers reviewed existing studies on the use of LHRH agonists in this setting, highlighting the potential for objective remissions and a favorable side-effect profile compared to standard chemotherapeutic agents. They emphasize the need for further research to clarify the efficacy of LHRH agonists in treating relapsed EOC.

Exploring New Avenues for Ovarian Cancer Treatment

This research offers a glimpse into the potential of LHRH agonists as a therapeutic option for relapsed EOC. The researchers' findings encourage further investigation into the use of LHRH agonists, potentially leading to new treatment strategies for this challenging condition.

Navigating the Shifting Sands of Ovarian Cancer Treatment

The researchers likened the search for effective ovarian cancer treatments to navigating a constantly shifting desert landscape. Just as a traveler must adapt their route to overcome obstacles, clinicians must explore new avenues to address the challenges of relapsed EOC. This study provides valuable insights into the potential of LHRH agonists, highlighting the need for continued research to optimize treatment options for this complex disease.

Dr.Camel's Conclusion

This study explores the potential of LHRH agonists as a treatment option for relapsed epithelial ovarian cancer. While promising, the research underscores the need for further research to clarify the efficacy of LHRH agonists and refine treatment strategies. This study highlights the ongoing quest for effective and safe treatments for challenging conditions like ovarian cancer, emphasizing the importance of continuous exploration and refinement of treatment options.

Date :
  1. Date Completed 2016-08-17
  2. Date Revised 2022-02-16
Further Info :

Pubmed ID

27356090

DOI: Digital Object Identifier

PMC6353126

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.